JP2019508403A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508403A5
JP2019508403A5 JP2018540794A JP2018540794A JP2019508403A5 JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5 JP 2018540794 A JP2018540794 A JP 2018540794A JP 2018540794 A JP2018540794 A JP 2018540794A JP 2019508403 A5 JP2019508403 A5 JP 2019508403A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
polynucleotide sequence
vaccine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508403A (ja
JP7123800B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016557 external-priority patent/WO2017136758A1/en
Publication of JP2019508403A publication Critical patent/JP2019508403A/ja
Publication of JP2019508403A5 publication Critical patent/JP2019508403A5/ja
Application granted granted Critical
Publication of JP7123800B2 publication Critical patent/JP7123800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540794A 2016-02-05 2017-02-03 がんのワクチン及びそれを用いた処置の方法 Active JP7123800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291601P 2016-02-05 2016-02-05
US62/291,601 2016-02-05
PCT/US2017/016557 WO2017136758A1 (en) 2016-02-05 2017-02-03 Cancer vaccines and methods of treatment using the same

Publications (3)

Publication Number Publication Date
JP2019508403A JP2019508403A (ja) 2019-03-28
JP2019508403A5 true JP2019508403A5 (enExample) 2020-03-19
JP7123800B2 JP7123800B2 (ja) 2022-08-23

Family

ID=59500919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540794A Active JP7123800B2 (ja) 2016-02-05 2017-02-03 がんのワクチン及びそれを用いた処置の方法

Country Status (10)

Country Link
US (4) US11007255B2 (enExample)
EP (1) EP3411122A4 (enExample)
JP (1) JP7123800B2 (enExample)
KR (2) KR20250002803A (enExample)
CN (2) CN118184761A (enExample)
AU (2) AU2017214656B2 (enExample)
BR (1) BR112018015893A2 (enExample)
CA (1) CA3013718C (enExample)
MX (2) MX2018009506A (enExample)
WO (1) WO2017136758A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018009506A (es) * 2016-02-05 2019-05-06 Inovio Pharmaceuticals Inc Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
WO2018217982A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same
WO2019086507A1 (en) 2017-10-31 2019-05-09 Pantarhei Bioscience B.V. Immunotherapeutic methods for treating and/or preventing lung cancer
CN111479585A (zh) 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向boris的癌症疫苗和其用途
US20220273691A1 (en) 2018-12-21 2022-09-01 Ionis Pharmaceuticals, Inc. Modulators of hsd17b13 expression
WO2021259963A1 (en) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunization against wnt4 for treatment and prophylaxis of breast cancer
CN118900696A (zh) 2021-10-19 2024-11-05 科学医疗有限责任公司 雄性避孕
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993024640A2 (en) 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
IL132103A0 (en) 1997-04-03 2001-03-19 Eletrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2504593C (en) 2002-11-04 2016-08-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
CA3184778A1 (en) * 2006-07-28 2008-01-31 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
PT3524316T (pt) 2006-10-17 2024-11-29 Inovio Pharmaceuticals Inc Dispositivos de eletroporação para eletroporação de células em mamíferos
US20090004716A1 (en) 2007-05-23 2009-01-01 Vgx Pharmaceuticlas, Inc. Compositions comprising high concentration of biologically active molecules and processes for preparing the same
US20140236070A1 (en) * 2011-07-29 2014-08-21 Kate Broderick Linear expression cassettes and uses thereof
WO2014144885A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
WO2014154905A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for dogs
US10398769B2 (en) * 2013-08-06 2019-09-03 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
MX2018009506A (es) * 2016-02-05 2019-05-06 Inovio Pharmaceuticals Inc Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
WO2018217982A1 (en) * 2017-05-26 2018-11-29 The Wistar Institute Of Anatomy And Biology Dtert vaccines and methods of treatment using the same

Similar Documents

Publication Publication Date Title
US20230293608A1 (en) Oncolytic Vaccinia Virus
JP2019193662A5 (enExample)
JP2015533841A5 (enExample)
Cerullo et al. Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans
RU2016145464A (ru) Рекомбинантные вакцинные штаммы listeria и способы их получения
PH12020500670A1 (en) Molecular adjuvant
WO2017205810A8 (en) Neoepitope vaccine compositions and methods of use thereof
JP2016516723A5 (enExample)
JP2016539946A5 (enExample)
WO2017209053A1 (ja) 新規な遺伝子組換えワクシニアウイルス
JP2016533749A5 (enExample)
RU2019107976A (ru) Композиция вакцины
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
RU2015103758A (ru) Днк-вакцина для применения у пациентов с раком поджелудочной железы
JP2020528911A5 (enExample)
JP2014207903A5 (enExample)
JP2015506179A5 (enExample)
JP2020511139A5 (enExample)
WO2011119925A3 (en) Synthetic herpes simplex viruses for treatment of cancers
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
RU2019132253A (ru) Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
JP2018522041A5 (enExample)
JP2014139185A5 (enExample)
JP2019508403A (ja) がんのワクチン及びそれを用いた処置の方法